Key Highlights
- Revenue from operations at ₹2,363 crore, up 20.4% YoY
- EBITDA at ₹460 crore, up 27.2% YoY; EBITDA margin at 19.5%
- Profit After Tax (PAT) at ₹231 crore, up 48.2% YoY
- PAT includes exceptional expense of ₹38 crore related to labour code changes
- Domestic business sales at ₹1,025 crore, up 15.4% YoY
- International business sales at ₹1,338 crore, up 24.5% YoY
Emcure Pharmaceuticals (BSE: 544210, NSE: EMCURE) today announced its consolidated financial results for the quarter ended December 31, 2025.
The quarter saw strong performance from both domestic and international businesses.
The domestic business grew 15.4%, led by strong performance across all key therapies, especially chronic segments including cardio/diabeto, and aided by new initiatives. During the quarter, the company launched Poviztra®, a biological injectable form of semaglutide, in India in partnership with Novo Nordisk. With Poviztra® (a global original innovator product), Emcure is well positioned to become a key player in the fast-emerging weight management segment.
The international business grew 24.5%, with all geographies reporting strong performance.
- Rest of the World (RoW) business grew 30.7%, led by strong performance in both non-ARV and ARV segments.
- Europe continued to see strong traction led by Manx and Amphotericin B rollout.
- Canada business recorded robust growth of 12.8%.
Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said:
“Q3 delivered a strong performance, with all our businesses outpacing industry growth. During the period, we strengthened our India portfolio with the launch of Poviztra®, a biological injectable semaglutide. Our international business continues to see strong growth led by the launch of our differentiated product pipeline. Emcure’s focus remains on improving profitability even as we invest in people, products and processes to drive strong growth.
We continue to augment our portfolio in all our focus markets through in-house R&D and in-licensing. The Novo Nordisk partnership has given Emcure an early-entry advantage, positioning us well in the fast-growing obesity segment. We remain focused on delivering strong growth along with margin improvement.”
